Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2011 / Cilt: 37 - Sayı: 1

Factors affecting recurrence and survival in patients who underwent radical prostatectomy for prostate cancer

Prostat kanseri nedeniyle radikal prostatektomi uygulanan hastalarda nüks ve sağkalımı etkileyen faktörler

Pages
1–8
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In patients with localized prostate cancer who underwent RP, patient recurrence can be predicted by evaluating clinical and pathological parameters.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We evaluated the factors affecting recurrence and survival of patients who underwent retropubic radical prostatectomy (RP) for localized prostate cancer.
📊
Key Findings & Data:Materials and methods: A total of 118 patients (mean age 66.8 years) who underwent RP between January 2001 and December 2009 in our clinic were evaluated retrospectively.
💡
Conclusion & Impact:Conclusion: In patients with localized prostate cancer who underwent RP, patient recurrence can be predicted by evaluating clinical and pathological parameters.
🔬Design:Research Article
📍Scope:2001 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: We evaluated the factors affecting recurrence and survival of patients who underwent retropubic radical prostatectomy (RP) for localized prostate cancer. Materials and methods: A total of 118 patients (mean age 66.8 years) who underwent RP between January 2001 and December 2009 in our clinic were evaluated retrospectively. The effects of clinical and pathologic parameters on recurrence were evaluated in 90 patients and the effects of these parameters on survival were evaluated in 100 patients. Results: Mean serum prostate specific antigen (PSA) level was 13.36 ng/mL. According to pathological stage, 6 patients were T2a (6.7%), 52 patients T2c (58.4%), 15 patients T3a (16.8%), 15 patients T3b (16.8%), and 1 patient T4a (1.1%). Of the patients, 33.1% had extraprostatic extension, 54.2% had perineural invasıon, 18.6% had seminal vesicle invasion, and 63.6% had positive surgical margins. Twenty-nine patients (32.2%) had recurrence. Mean time to recurrence was 18.4 months. In multivariate analysis, pathological stage, serum PSA, positive biopsy core number and percent, seminal vesicle invasion, extraprostatic extension, perineural invasion, Gleason grade, surgical margin positivity, presence of high grade prostatic intraepitelial neoplasia and high risk tumor according to D’Amico risk stratification were significant parameters affecting the recurrence rate. Conclusion: In patients with localized prostate cancer who underwent RP, patient recurrence can be predicted by evaluating clinical and pathological parameters.

Özet

Amaç: Bu çalışmada lokalize prostat kanseri nedeniyle retropubik radikal prostatektomi (RP) operasyonu yapılan hastalarda nüks ve sağkalımı etkileyen faktörleri araştırdık. Gereç ve yöntem: Kliniğimizde Ocak 2001 ile Aralık 2009 tarihleri arasında RP operasyonu yapılan 118 hasta (ortalama yaş 66.8) retrospektif olarak değerlendirildi. Nüks üzerine etkili klinik ve patolojik parametreler 90 hasta üzerinden, sağkalıma etkili parametler 100 hasta üzerinden değerlendirildi. Bulgular: Hastaların ortalama serum prostat spesifik antijen (PSA) değeri 13.36 ng/mL idi. Patolojik evre dağılımı 6 hastada T2a (%6.7), 52 hastada T2c (%58.4), 15 hastada T3a (%16.8), 15 hastada T3b (%16.8) ve 1 hastada T4a (%1.1) idi. Hastaların %33.1’inde ekstraprostatik yayılım, %54.2’sinde perinöral invazyon, %18.6’sında seminal vezikül invazyonu ve %63.6’sında cerrahi sınır pozitifliği saptandı. Nüks 29 hastada (%32.2) mevcuttu. Ortalama nüks zamanı 18.4 ay idi. Multivaryant analizde patolojik evre, serum PSA değeri, pozitif biyopsi kor sayısı ve yüzdesi, seminal vezikül invazyonu, ekstraprostatik yayılım, perinöral invazyon, Gleason skoru, cerrahi sınır pozitifliği, high grade prostatik intraepitelyal neoplazi varlığı ve D’Amico risk sınıflamasına göre yüksek risk grubu nüks oranını anlamlı olarak etkileyen faktörler olarak belirlendi. Sonuç: Lokalize prostat kanseri nedeniyle RP operasyonu uygulanan hastalarda klinik ve patolojik faktörler değerlendirilerek nüks hakkında öngörüde bulunabilmek mümkündür.

🔖

Cite This Article

ÖZTÜRK, C., GÖRGEL, S. N., BAYIR, O., KAYGISIZ, M., BAL, K., BÖLÜKBAŞI, A. (2011). Factors affecting recurrence and survival in patients who underwent radical prostatectomy for prostate cancer. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 37 - Sayı: 1, 1–8. https://ajindex.com/articles/328080

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Hinman F Jr. Atlas of urosurgical anatomy. Philadelphia: W.B.Saunders Co; 1993
  2. Billis A, Watanabe IC, Costa MV, Telles GH, Magna LA. Iatrogenic and non-iatrogenic positive margins: incidence, site, factors involved, and time to PSA progression following radical prostatectomy. Int Urol Nephrol 2008;40:105-11. doi:10.1007/s11255-007-9198-6 PMid:17619165 3. Brimo F, Partin AW, Epstein JI. Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis. Urology 2010;76:1206-9. doi:10.1016/j.urology.2010.03.090 PMid:20692688 4. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-42. PMid:7523731 5. Neulander EZ, Solovay MS. Failure after radical prostatectomy. Urology 1997;61:287-92
  3. Feedland SJ, Sutter ME, Dorey F, Anonson WJ. Defining the ideal cut-point for determining PSA recurrence after prostatectomy. Urology 2003;61:365-9. doi:10.1016/S0090-4295(02)02268-9 7. Aus G, Abbou CC, Pacik D, Schmid HP, van Poppel H, Wolff JM, et al. EAU guidelines on prostate cancer. Eur Urol 2001;40:97-101. doi:10.1159/000049758 PMid:11528184 8. Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 2004;58:382-90. doi:10.1111/j.1368-5031.2004.00184.x PMid:15161124 9. Fichner J. The management of prostate cancer in patient with a rising prostate-spesific antigen level. BJU Int 2000;86:181-90. doi:10.1046/j.1464-410x.2000.00701.x 10. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation after radical prostatectomy. JAMA 1999;281:1591-7. PMID: 10235151 11. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive cases. J Urol 2002;167:528-34. doi:10.1016/S0022-5347(01)69079-7 PMid:11792912 doi:10.1097/00005392-200202000-00018 12. Wieder JA, Soloway MS. Incidence etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 1998;160:299-315. doi:10.1016/S0022-5347(01)62881-7 PMid:9679867 doi:10.1097/00005392-199808000-00003 PMid:20723925 13. Budäus L, Isbarn H, Eichelberg C, Lughezzani G, Sun M, Perrotte P, et al. Biochemical recurrence after radical prostatectomy: multiplicative interaction